Four key Asian markets witnessed nearly 200 life science company listings over the past 10 years, with China dominating the scene and expected to stay ahead, along with Hong Kong, for the foreseeable future. But India could prove a new contender over time as firms move up the value chain, a new report shows.
The key life sciences hubs in Asia - China, Hong Kong, India and Singapore - witnessed close to 200 initial public offerings (IPOs) across the sector between 2010-19, with China topping the charts and accounting for the bulk of the listings and total capital raised, according to a new study.
The four Asian markets together saw 196 listings that raised a total of $27.6bn over the past 10 years, with the vast majority of the IPOs being in the pharma and biotech segments
The German biotech has been forced into insolvency and NASDAQ suspension.
Investors welcomed Bavarian Nordic’s and Bayer’s earnings announcements. However, both stock prices declined over the day of their reports as the impact of recent pressures weighed.
Roche Pharmaceuticals’ area head, Asia Pacific, outlines how the Swiss group is helping nurture the wider ecosystem and setting itself up for a bigger play in the ophthalmology space by combining scientific expertise with regional insights.
The first of two Phase III trials in obstructive sleep apnea showed Apnimed’s combination pill can offer a therapeutic alternative to entrenched CPAP devices.
